IDEXX Laboratories, Inc. - Common Stock (IDXX)

IDEXX Laboratories (IDXX) is a high-quality stock with strong revenue growth, exceptional profitability, and solid financial health, making it a compelling pick for long-term investors.

A fundamental analysis of (NASDAQ:IDXX): Why NASDAQ:IDXX Stands Out as a Quality Stock.

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

The company has adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.

Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Every stock tells a story; it takes humans to find the meaning in it.

Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments.

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.

The company sells diagnostic equipment for veterinarians. Fourth-quarter metrics grew and beat expectations.

Wall Street bounced back after President Donald Trump and Mexican President Claudia Sheinbaum agreed to a one-month suspension of tariffs following Mexico's pledge to bolster its military presence at the northern borde

Idexx Laboratories posted strong Q4 earnings, beating estimates with 10% EPS growth. 2025 guidance reflects up to 7% revenue growth and $1.5 billion in buybacks.